Blue Fin Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $450K | Sell |
16,019
-23
| -0.1% | -$612 | 0.07% | 105 |
|
|
2025
Q4 | $399K | Sell |
16,042
-967
| -6% | -$24.4K | 0.06% | 116 |
|
|
2025
Q3 | $433K | Sell |
17,009
-1,327
| -7% | -$32.8K | 0.07% | 106 |
|
|
2025
Q2 | $444K | Sell |
18,336
-3,883
| -17% | -$90.6K | 0.08% | 103 |
|
|
2025
Q1 | $563K | Sell |
22,219
-513
| -2% | -$13.4K | 0.11% | 92 |
|
|
2024
Q4 | $603K | Sell |
22,732
-2,191
| -9% | -$59.4K | 0.11% | 89 |
|
|
2024
Q3 | $721K | Sell |
24,923
-2,131
| -8% | -$62.2K | 0.14% | 87 |
|
|
2024
Q2 | $757K | Sell |
27,054
-1,930
| -7% | -$53.1K | 0.15% | 82 |
|
|
2024
Q1 | $804K | Sell |
28,984
-5,986
| -17% | -$166K | 0.18% | 80 |
|
|
2023
Q4 | $1.01M | Sell |
34,970
-8,704
| -20% | -$263K | 0.26% | 70 |
|
|
2023
Q3 | $1.45M | Sell |
43,674
-205
| -0.5% | -$7.25K | 0.42% | 55 |
|
|
2023
Q2 | $1.61M | Sell |
43,879
-21
| -0% | -$817 | 0.46% | 49 |
|
|
2023
Q1 | $1.68M | Sell |
43,900
-2,801
| -6% | -$121K | 0.54% | 42 |
|
|
2022
Q4 | $2.39M | Sell |
46,701
-562
| -1% | -$26.9K | 0.88% | 33 |
|
|
2022
Q3 | $2.07M | Buy |
47,263
+2,197
| +5% | +$107K | 0.78% | 38 |
|
|
2022
Q2 | $2.36M | Buy |
45,066
+118
| +0.3% | +$6.01K | 0.84% | 34 |
|
|
2022
Q1 | $2.33M | Buy |
44,948
+270
| +0.6% | +$14K | 0.67% | 40 |
|
|
2021
Q4 | $2.64M | Buy |
44,678
+78
| +0.2% | +$3.87K | 0.73% | 35 |
|
|
2021
Q3 | $1.92M | Sell |
44,600
-409
| -0.9% | -$18.1K | 0.59% | 43 |
|
|
2021
Q2 | $1.76M | Sell |
45,009
-1,307
| -3% | -$50.8K | 0.54% | 47 |
|
|
2021
Q1 | $1.68M | Buy |
46,316
+183
| +0.4% | +$6.5K | 0.58% | 48 |
|
|
2020
Q4 | $1.7M | Sell |
46,133
-1,281
| -3% | -$47K | 0.61% | 44 |
|
|
2020
Q3 | $1.65M | Buy |
47,414
+1,915
| +4% | +$67.1K | 0.67% | 39 |
|
|
2020
Q2 | $1.41M | Sell |
45,499
-1,091
| -2% | -$37.1K | 0.62% | 42 |
|
|
2020
Q1 | $1.44M | Buy |
46,590
+1,368
| +3% | +$46.6K | 0.8% | 37 |
|
|
2019
Q4 | $1.68M | Sell |
45,222
-506
| -1% | -$18K | 0.79% | 35 |
|
|
2019
Q3 | $1.56M | Sell |
45,728
-1,083
| -2% | -$39.4K | 0.82% | 35 |
|
|
2019
Q2 | $1.92M | Buy |
46,811
+91
| +0.2% | +$3.61K | 0.99% | 29 |
|
|
2019
Q1 | $1.88M | Sell |
46,720
-1,239
| -3% | -$49.6K | 0.99% | 26 |
|
|
2018
Q4 | $1.99M | Sell |
47,959
-813
| -2% | -$33.7K | 1.19% | 20 |
|
|
2018
Q3 | $2.04M | Buy |
48,772
+495
| +1% | +$19.1K | 1.01% | 26 |
|
|
2018
Q2 | $1.66M | Buy |
48,277
+680
| +1% | +$23.2K | 0.89% | 30 |
|
|
2018
Q1 | $1.6M | Sell |
47,597
-676
| -1% | -$23.2K | 0.9% | 29 |
|
|
2017
Q4 | $1.66M | Buy |
48,273
+316
| +0.7% | +$10.8K | 0.97% | 24 |
|
|
2017
Q3 | $1.62M | Sell |
47,957
-179
| -0.4% | -$5.75K | 1% | 27 |
|
|
2017
Q2 | $1.53M | Sell |
48,136
-1,070
| -2% | -$33.7K | 0.99% | 30 |
|
|
2017
Q1 | $1.6M | Sell |
49,206
-696
| -1% | -$21.9K | 0.98% | 32 |
|
|
2016
Q4 | $1.54M | Buy |
49,902
+7,719
| +18% | +$236K | 1.02% | 30 |
|
|
2016
Q3 | $1.36M | Sell |
42,183
-2,741
| -6% | -$91.7K | 1.1% | 28 |
|
|
2016
Q2 | $1.5M | Sell |
44,924
-574
| -1% | -$18.3K | 1.24% | 24 |
|
|
2016
Q1 | $1.28M | Sell |
45,498
-6,740
| -13% | -$193K | 1.09% | 27 |
|
|
2015
Q4 | $1.6M | Buy |
52,238
+1,132
| +2% | +$35.6K | 1.23% | 23 |
|
|
2015
Q3 | $1.52M | Sell |
51,106
-1,344
| -3% | -$43.1K | 1.19% | 22 |
|
|
2015
Q2 | $1.67M | Sell |
52,450
-654
| -1% | -$21.3K | 1.2% | 21 |
|
|
2015
Q1 | $1.75M | Buy |
53,104
+1,634
| +3% | +$51.9K | 1.27% | 20 |
|
|
2014
Q4 | $1.52M | Buy |
51,470
+3,557
| +7% | +$102K | 1.15% | 23 |
|
|
2014
Q3 | $1.34M | Buy |
47,913
+1,075
| +2% | +$30.2K | 1.07% | 26 |
|
|
2014
Q2 | $1.32M | Buy |
46,838
+870
| +2% | +$24.8K | 1.06% | 24 |
|
|
2014
Q1 | $1.4M | Sell |
45,968
-1,557
| -3% | -$46.4K | 1.23% | 23 |
|
|
2013
Q4 | $1.38M | Buy |
+47,525
| New | +$1.38M | 1.23% | 21 |
|
Other funds holding PFE
VCM
VPM
Blue Fin Capital's PFE Position: Q1 2026 in Review
Blue Fin Capital reduced its Pfizer (PFE) stake by 0.14% in Q1 2026, selling an estimated $612 and leaving 16,019 shares worth $450K. The position accounts for 0.07% of the portfolio, ranked #105.
Blue Fin Capital first reported a position in PFE in Q4 2013 and has held it in 50 quarters since. The position peaked at $2.64M in Q4 2021. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Blue Fin Capital held 16,019 shares of Pfizer worth $450K as of Q1 2026.
- Blue Fin Capital sold 23 Pfizer shares in Q1 2026, an estimated $612.
- Pfizer made up 0.07% of Blue Fin Capital's portfolio in Q1 2026, its #105 holding.
- Blue Fin Capital first reported a position in Pfizer in Q4 2013 and has held it in 50 quarters since.
- Blue Fin Capital's Pfizer position peaked at $2.64M in Q4 2021.
- 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Blue Fin Capital's 13F filing for Q1 2026, filed 28 May 2026.